242 related articles for article (PubMed ID: 9456263)
1. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia.
Simonelli C; Zanussi S; Comar M; Vaccher E; Giacca M; De Paoli P; Tirelli U
AIDS; 1998 Jan; 12(1):112-3. PubMed ID: 9456263
[No Abstract] [Full Text] [Related]
2. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
Molina JM; Chêne G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM
J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849
[TBL] [Abstract][Full Text] [Related]
3. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
4. Focusing on the second phase of plasma HIV-1 RNA clearance.
Lafeuillade A; Poggi C; Sayada C; Pellegrino P; Profizi N
AIDS; 1997 Feb; 11(2):264-6. PubMed ID: 9030385
[No Abstract] [Full Text] [Related]
5. Effect of combined zidovudine and didanosine therapy in early asymptomatic primary HIV-1 infection.
Khajotia RR; Feigley CE; Lee E; Gu J
AIDS; 1998 Jan; 12(2):222-4. PubMed ID: 9468376
[No Abstract] [Full Text] [Related]
6. Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2.
Stellbrink HJ; Hufert FT; Tenner-Racz K; Lauer J; Schneider C; Albrecht H; Racz P; van Lunzen J
Antivir Ther; 1998; 3(4):209-14. PubMed ID: 10682140
[TBL] [Abstract][Full Text] [Related]
7. Closing the circle on HIV--or not.
Mascolini M
J Int Assoc Physicians AIDS Care; 1995 Oct; 1(9):10-4, 17-29 contd. PubMed ID: 11362964
[TBL] [Abstract][Full Text] [Related]
8. Zidovudine plus didanosine in primary HIV-1 infection.
Perrin L; Yerly S; Charvier A; Figueras G; Schockmel GA; Hirschel B
Antivir Ther; 1997 Jan; 2(1):5-11. PubMed ID: 11322267
[TBL] [Abstract][Full Text] [Related]
9. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD
Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
Foli A; Lori F; Maserati R; Tinelli C; Minoli L; Lisziewicz J
Antivir Ther; 1997 Jan; 2(1):31-8. PubMed ID: 11322264
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of combining zidovudine plus didanosine in patients with and without previous exposure to zidovudine].
Gómez-Cano M; Soriano V; García-Lerma G; González-Lahoz J
An Med Interna; 1998 Mar; 15(3):145-7. PubMed ID: 9567422
[TBL] [Abstract][Full Text] [Related]
13. Impact of antiretroviral therapy on hepatitis C viraemia in HIV-infected patients.
Bravo R; Soriano V; García-Samaniego J; Gómez-Cano M; González-Lahoz J; Altisent C; Ruiz I
Antivir Ther; 1996 Aug; 1(3):194. PubMed ID: 11322254
[No Abstract] [Full Text] [Related]
14. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RT; Allende MC; Lane HC
J Infect Dis; 2000 May; 181(5):1614-21. PubMed ID: 10823761
[TBL] [Abstract][Full Text] [Related]
15. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
Jankelevich S; Mueller BU; Mackall CL; Smith S; Zwerski S; Wood LV; Zeichner SL; Serchuck L; Steinberg SM; Nelson RP; Sleasman JW; Nguyen BY; Pizzo PA; Yarchoan R
J Infect Dis; 2001 Apr; 183(7):1116-20. PubMed ID: 11237839
[TBL] [Abstract][Full Text] [Related]
16. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.
Yerly S; Denereaz N; Mermillod B; Hirschel B; Perrin L
Antivir Ther; 1996 Aug; 1(3):167-71. PubMed ID: 11322250
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
Kojima E; Shirasaka T; Anderson BD; Chokekijchai S; Steinberg SM; Broder S; Yarchoan R; Mitsuya H
J Infect Dis; 1995 May; 171(5):1152-8. PubMed ID: 7751690
[TBL] [Abstract][Full Text] [Related]
20. [Anti-retroviral treatment. Approach to previously treated patients].
Antela A; Podzamczer D; Ruiz I; Parras F
Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():24-30. PubMed ID: 9053023
[No Abstract] [Full Text] [Related]
[Next] [New Search]